Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 266.00
- Piotroski Score 2.00
- Grade Buy
- Symbol (THM)
- Company International Tower Hill Mines Ltd.
- Price $0.43
- Changes Percentage (1.95%)
- Change $0.01
- Day Low $0.42
- Day High $0.44
- Year High $0.80
International Tower Hill Mines Ltd., a mineral exploration company, engages in the acquisition, exploration, and development of mineral properties. It holds or has rights to acquire interests in the Livengood gold project covering an area of approximately 19,546 hectares located to the northwest of Fairbanks, Alaska. The company was formerly known as Tower Hill Mines Ltd. and changed its name to International Tower Hill Mines Ltd. in March 1991. International Tower Hill Mines Ltd. was incorporated in 1978 and is headquartered in Vancouver, Canada.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/05/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.02
- Trailing P/E Ratio -29.18
- Forward P/E Ratio -29.18
- P/E Growth -29.18
- Net Income $-3,397,969
Income Statement
Quarterly
Annual
Latest News of THM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Rithm Capital's (NYSE:RITM) five-year earnings growth trails the 2.3% YoY shareholder returns
Investors aim to outperform market index funds by selecting individual stocks. Although Rithm Capital's stock has declined by 30% in five years, recent uptick and EPS growth suggest positive signs. Ho...
By Yahoo! Finance | 6 days ago -
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
Tezspire has shown significant reduction in nasal polyp size and congestion in a study. It's being evaluated for severe chronic rhinosinusitis with nasal polyps and approved for severe asthma. Further...
By Yahoo! Finance | 1 week ago -
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
To advance a Daybreak trial population to a pivotal study, understanding genetic variants is crucial. Real-world data from French HO patients predicts positive Phase 3 outcomes. International market g...
By Yahoo! Finance | 1 week ago
